pSivida Corp (PSDV.OQ)
22 Dec 2014
|Market Cap (Mil.):||$125.31|
|Shares Outstanding (Mil.):||29.35|
- Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.
Sept 26 - Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.
Sept 26 - The Food and Drug Administration has approved Alimera Sciences Inc's and pSivida Corp's vision-loss treatment Iluvien after three rejections.
|Allergan, Inc. (AGN.N)||$212.63||+0.45|
|Regeneron Pharmaceuticals Inc (REGN.OQ)||$427.64||+3.85|
|Roche Holding Ltd. (ROG.VX)||CHF270.40||-18.30|
|QLT Inc. (QLT.TO)||$4.30||+0.12|
|GlaxoSmithKline Pakistan Limited (GLAX.KA)||₨222.65||-3.65|
|ThromboGenics NV (THR.BR)||€6.45||+0.06|
|Santen SAS (NOVPEUR.PAp)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
"The Economy Matters" Report for PSDV: the economy's impact on PSDV's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: S&P Capital IQ Quantitative Report
pSivida Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.